Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCRUED EXPENSES (Details)

v3.23.1
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued pre-clinical and clinical costs $ 4,074,713 $ 2,137,317
Accrued product development costs 409,691 247,500
Accrued compensation 826,703 2,224,951
Accrued administrative costs 143,175 473,376
Accrued interest 1,014,020 916,108
Total $ 6,468,302 $ 5,999,252